1,975.60
+9.7(+0.49%)
Currency In INR
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
14989
First IPO Date
July 01, 2002
| Name | Title | Pay | Year Born |
| Mr. Glenn Mario Saldanha | Chairman, MD & Chief Executive Officer | 180.67M | 1970 |
| Ms. Cherylann Maria Pinto B.Pharm | Executive Director of Corporate Services & Executive Director | 62.25M | 1967 |
| Mr. Alind Sharma | President and Chief Human Resources Officer | 0 | 1971 |
| Mr. Marc T. Kikuchi B.A., M.B.A. | President & Business Head of North America | 0 | 1969 |
| Mr. Ulhas R. Dhuppad | President & Head of Global Pharmaceutical Development | 0 | 1967 |
| Mr. Christoph Stoller | President and Business Head of Europe & Emerging Markets | 0 | N/A |
| Mr. Harish Vinayak Kuber | Company Secretary & Compliance Officer | 0 | N/A |
| Mr. Brijlal Motwani | President & Chief Quality Officer | 0 | N/A |
| Mr. Indrajit Bose | President & Chief Quality Officer | 0 | N/A |
| Mr. Alok Malik | President & Business Head of India Formulations | 0 | N/A |
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and markets pharmaceutical products in India, North America, Latin America, Europe, and internationally. The company provides branded and generic formulations in the therapeutic areas of dermatology, respiratory, and oncology; and various active pharmaceutical ingredients. Its product pipeline includes ISB 830 (telazorlimab), an OX40 antagonist monoclonal antibody, which is in Phase 2b clinical trial for the treatment of atopic dermatitis; ISB 1302, a HER2 X CD3 beat bispecific antibody that is in Phase 1/2 clinical trial for the treatment of metastatic HER2-positive breast cancer; and ISB 1342, a CD38 X CD3 beat bispecific antibody, which is in Phase 1 clinical trial for the treatment of relapsed/refractory multiple myeloma. The company's pre-clinical stage product pipeline comprises ISB 880 for the treatment of anti-inflammatory therapy; ISB 1908 and ISB 1909 T-cell engagers for the treatment of oncology; ISB 1442, an innate immune engager for the treatment of oncology; and GRC 39815, an inhibitor of the retinoid-related orphan receptor gamma for the treatment of chronic obstructive pulmonary disorder. It also offers Ryaltris nasal spray for allergic rhinitis. The company was incorporated in 1977 and is based in Mumbai, India.